- About Us
- Nano-Social Network
- Nano Consulting
- My Account
November 30th, 2007
Biotech Corp acquires exclusive worldwide license to nanotechnology platform
Malaysian Biotechnology Corporation (Biotech Corp) has acquired its first technology acquisition from Nanobiotix, a French start-up company, for an undisclosed amount.
Nanobiotix develops nanotechnology applications for cancer therapy. However, Biotech Corp is licensing the nanotechnology platform for non-cancer purposes.
Nanobiotix founder and chief executive officer Dr Laurent Levy said this would allow it to concentrate its resources on oncology applications while expanding its potential pipeline into non-cancer areas via Biotech Corp.
The license will provide access to the application of high-level nanotechnology in the country, said BioTech Corp chief executive officer Datuk Iskandar Mizal Mahmood at the launch on Nov 30.
|Related News Press|
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017
Strength of hair inspires new materials for body armor January 18th, 2017
Leti to Tackle Tomorrow's Research Strategies with Stanford University’s SystemX Alliance: French R&D Center Is the First Research Institute to Join the Collaboration and Provides Bridges Between Academia and Industry, Leveraging Alliance’s Potential October 4th, 2016
Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016
NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016